Abbvie
Under the agreement, Boehringer will to pay AbbVie royalties for licensing its Humira patents and agreed to acknowledges the validity and enforceability of the patents, AbbVie said.
May 15, 2019 at 03:59 PM
1 minute read
AbbVie Inc. has settled its Delaware patent infringement suit against Boehringer Ingelheim, granting the German drugmaker a nonexclusive license to begin selling a biosimilar of its $20 billion immunosuppressant Humira in 2023.
The companies announced the settlement with a pair of press releases Tuesday. Under the agreement, Boehringer will to pay AbbVie royalties for licensing its Humira patents and agreed to acknowledges the validity and enforceability of the patents, AbbVie said.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
